Neovasc Inc

Neovasc — Investor Presentation (November 2014)

23 slides from Neovasc's investor presentation, November 2014

  1. Slide 1: Revolutionizing how advanced heart disease is treated

    Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Breakthrough products for refractory angina and mitral valve disease

    Breakthrough products for refractory angina and mitral valve disease Collaborations with leading companies Commercial products and established revenues 3

  4. Slide 4: 3 product lines targeting 3 significant markets

    3 product lines Targeting 3 significant markets Biologicial Tissue Tiara™ Reducer™ Proprietary biological Transcatheter mitral Transcatheter device for tissue products for valve replacement refractory angina implantable medical devices 4

  5. Slide 5: Our Biological Tissue Business

    Our Biological Tissue Business Working with industry leaders to improve patient care

  6. Slide 6: Biological Tissue

    Biological Tissue Proprietary process with 25+ year implant history • Implantable tissue from animal pericardium • Retains strength & physical characteristics of natural tissue • Used in implantable medical devices including transcatheter heart valves 6

  7. Slide 7: Biological Tissue: Profitable and growing business

    Biological Tissue Profitable and growing business Supports Neovasc infrastructure and internal development programs 18 16 14 12 $ millions 10 49% cagr 8 6 4 2 0 2008 2009 2010 2011 2012 2013 2014 (Estimated) 7

  8. Slide 8: Tiara Transcatheter Mitral Valve

    Tiara™ Transcatheter Mitral Valve

  9. Slide 9: Minimally invasive treatment for the most common form of valvular heart disease

    Minimally invasive treatment for the most common form of valvular heart disease 9

  10. Slide 10: Mitral Valve Regurgitation (MR)

    Mitral Valve Regurgitation (MR) Occurs when the valve that separates the atrium from the ventricle on the left side of the heart does not close properly allowing blood to flow back into the atrium during systole M I T R AL R E G U RG I TAT I O N Results in: • shortness of breath VALVE D OES N OT FU

  11. Slide 11: Tiara Addressable market opportunity

    Tiara Addressable market opportunity Success of transcatheter aortic valves (TAVI) has positioned transcatheter mitral valve implantation (TMVI) as a major area of clinical/ industry interest • ~4 million people suffer from MR in the US, similar population in EU • ~40% have symptoms eligible for tre

  12. Slide 12: Tiara: A novel transcatheter mitral valve replacement

    Tiara A novel transcatheter Mitral Valve replacement COMPLETELY REPLACES THE DISEASED VALVE • Design is specific to mitral anatomy • Multiple anchors resist high dislodgment forces • Does not obstruct LVOT and preserves LV function • Quick and repeatable implantation procedure • Transapical delivery

  13. Slide 13: Tiara: First human implant January 2014

    Tiara January 2014 - First Human implant of Tiara Conducted by internationally recognized team at St. Paul’s Hospital, Vancouver, Canada EXCELLENT RESULTS FROM FIRST CASES • No procedural complications • Typically less than 20 min to enter heart through apex and implant valve • Complete resolution o

  14. Slide 14: TIARA-I early feasibility study

    TIARA- I Multinational, multicenter early feasibility study in the US, Canada, EU • Observational study of high-risk (operable) patients • Co-Chairs of Study Committee: • Dr. Martin Leon • Dr. Anson Cheung • Enroll up to 30 patients (~15 US, ~15 EU) • Primary endpoints will be procedural success and

  15. Slide 15: Reducer Refractory Angina Therapy

    Reducer™ Refractory Angina Therapy

  16. Slide 16: Debilitating condition without treatment options

    Debilitating condition without treatment options 16

  17. Slide 17: Refractory Angina

    Refractory Angina Constant, severe chest pain ~2,000,000 refractory angina patients in each of US & EU ~10,000,000 patients/year treated for “recurrent” angina C AU S E D BY I N AD E Q UAT E B LO O D F LOW TO AR E AS O F T HE HEART M US C LE T HAT C AN N OT B E M AN AGED T HROUGH C O N VE N T I O N

  18. Slide 18: Reducer: 20 minute catheter-based procedure

    Reducer 20 minute catheter-based procedure • Implanted in the coronary sinus (large vein in heart) • Hourglass shape modulates flow of blood in the heart to elevate CS pressure • Re-distributing blood and increasing flow to ischemic areas in the endocardium Reducer modulates flow to elevate CS press

  19. Slide 19: Reducer: COSIRA study primary endpoint achieved

    Reducer COSIRA study primary endpoint achieved Double-blind, randomized, sham-controlled, multicenter prospective trial • n = 104 patients (in EU and Canada) • Patients randomized 1:1 to blinded treatment & sham control arms • Improvement of ≥2 angina CCS classes (primary endpoint) occurred 2.3x mor

  20. Slide 20: Reducer Next steps

    Reducer Next steps • Expand enrollment in European Registries • Initiate US IDE Study required for FDA approval • Introduce product into pilot centers in Europe • Explore partnerships for EU full commercial launch 20

  21. Slide 21: Financials: Cash on hand to achieve milestones

    Financials Cash on hand to achieve milestones for 2014/2015 • Completed C$25m financing March 2014, $6/share • Current cash position ~$20m (no material debt) • Listed on TSX and NASDAQ Neovasc has ~150 employees located at its facility in Vancouver, Canada and ~10 clinical and regulatory affairs emp

  22. Slide 22: Looking forward

    Looking forward • Tiara Program – Complete TIARA-I in 2015 – Target to initiate CE mark trial in 2015 – Target to initiate pivotal US trial in 2016 • Reducer Program – Initiate US FDA trial in 2015 – Launch product in pilot sites (EU/ROW) in 2015 • Tissue Business – Continue to support infrastructur

  23. Slide 23: Thank you

    Thank you Alexei Marko, CEO Chris Clark, CFO November 2014

Neovasc — Investor Presentation (November 2014) on 6ix